Astrocytoma

Oncology·MeSH: Astrocytoma

Prevalence

5.0 / 100K

17 drugs in development·11 companies·5 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
afinitor	Novartis AG (NVS)
carmustine	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(4)

Drug	Company
A10 and AS2-1 Antineoplaston	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Antineoplastons (A10 & AS2-1)	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Antineoplastons (A10 and AS2-1)	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Temozolomide	CG Oncology, Inc. (CGON)

Phase 2(2)

Drug	Company
Telaglenastat Hydrochloride	Black Diamond Therapeutics, Inc. (BDTX)
Tuvusertib	Merus N.V. (MRUS)

Phase 1(5)

Drug	Company
mb-101	MUSTANG BIO, INC. (MBIO)
mb-109	Fortress Biotech Inc. (FBIO)
mb-109	MUSTANG BIO, INC. (MBIO)
pritumumab	Nascent Biotech Inc. (NBIO)
Vorinostat	Black Diamond Therapeutics, Inc. (BDTX)

Phase 1/Phase 2(4)

Drug	Company
cynk-001 systemic	Celularity Inc. (CELU)
CYNK-101	Celularity Inc. (CELU)
folfiri protocol	NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
neo212	NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)

BioSniper tracks 17 drugs in development for Astrocytoma across 11 companies.

There are 5 clinical trials targeting Astrocytoma tracked by BioSniper.

The estimated prevalence of Astrocytoma is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.